Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there''s one clear-cut stock-split stock that''s notably cheaper than the rest.

As of September 19, S&P 500 healthcare stocks were down 3.2% for the year. Of the 11 sectors, its year to date ( YTD ) performance is the second worst only behind utilities. Over the past decade, the Health Care Select Sector SPDR Fund (NYSEARCA: XLV ) has fared better, averaging an annualized return of 12.23%, putting it in third spot. However, the tech-heavy index has a weighting of 27.13% , or double that of healthcare. The XLV trails the SPDR S&P 500 ETF Trust (NYSEARCA: SPY ) by 48 basis points. Nonetheless, if you can only have one sector ETF in your investment portfolio, it should be healthcare. No other sector has such a profound effect on the overall financial well-being of a country. So let’s explore three healthcare stocks to buy now. BioTechne (TECH) Source: shutterstock.com/Romix Image BioTechne (NASDAQ: TECH ) is a small holding in XLV with just a 0.22% weighting. Barron’s recently produced an article about six healthcare stocks in the S&P 500 with buy ratings, with more than 70% of the analysts covering the stocks.

Gateway Investment Advisers LLC decreased its holdings in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 33.8% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 65,589 shares of the medical device company’s stock after selling 33,527 shares during the quarter. Gateway Investment Advisers LLC’s holdings in DexCom were worth $8,429,000 as of its most recent […]

… during the period. Gateway Investment Advisers LLC’s holdings in … number of other large investors also recently bought and sold … the last quarter. Institutional investors and hedge funds own 93 … $139.55. Want More Great Investing Ideas? DexCom (NASDAQ:DXCM – …

A remarkable 30-year bull run for the Nasdaq 100 saw it gain nearly 4,000% by 2020. But, the party came to a screeching halt when the pandemic hit. Within a matter of weeks the tech-heavy index lost a third of its value and plunged deep into a bear market. Yet just as quickly, it made a U-turn and more than doubled again over the next 18 months. While that roller coaster ride was intense, it’s been a bit rocky since, and the Nasdaq 100 still hasn’t regained those former highs. It is within striking distance, though, sitting just 7% below its former peak. For investors with a long-term mindset, this means bargains still abound. What follows are three unstoppable Nasdaq stocks to buy right now. DexCom (DXCM) Source: FOOTAGE VECTOR PHOTO / Shutterstock.com Medical device manufacturer DexCom (NASDAQ: DXCM ) specializes in continuous glucose monitors ( CGM ) used by diabetics and is the second largest player behind Abbott Labs (NYSE: ABT ). In the market for Type 1 diabetes, though, DexCom is the leader by a better than 2-to-1 margin.

Steven R Altman , Board Member at DexCom (NASDAQ: DXCM ), reported a large insider sell on September 19, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Altman sold 1,000 shares of DexCom . The total transaction amounted to $101,495. DexCom shares are trading down 0.28% at $93.9 at the time of this writing on Wednesday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. The Importance of Insider Transactions Insider transactions shouldn''t be used primarily to make … Full story available on Benzinga.com

DexCom, a company listed on the NASDAQ under the symbol DXCM, has recently attracted attention due to unusual options activity. This activity suggests that a large investor or institution has taken a bullish stance on the stock. Benzinga’s options scanner has identified 12 uncommon options trades for DexCom, with an equal split of 50% bullish […] The post Unusual Options Activity and Sentiment for DexCom appeared first on Best Stocks .

Unveiling DexCom (DXCM)''s Value: Is It Really Priced Right? A Comprehensive Guide

https://www.investing.com/news/stock-market-news/dexcom-stock-rebounds-amidst-inflation-control-efforts-faces-potential-threats-from-obesity-drugs-93CH-3176754

A note from an increasingly cautious pundit may have created a downdraft for this high-flying glucose monitor company.